Annual report pursuant to Section 13 and 15(d)

INTEREST EXPENSE AND FINANCING FEES (Tables)

v3.22.1
INTEREST EXPENSE AND FINANCING FEES (Tables)
12 Months Ended
Dec. 31, 2021
INTEREST EXPENSE AND FINANCING FEES  
Schedule of interest expense and financing fees

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Year Ended December 31, 

​

​

2021

​

2020

($in thousands)

    

Interest

    

Fees1

    

Total

    

Interest

    

Fees1

    

Total

Convertible preferred shares

​

$

2,845

​

$

2,572

​

$

5,417

​

$

—

​

$

—

​

$

—

Dividend payable

​

 

820

​

 

—

​

 

820

​

 

—

​

 

—

​

 

—

Installment payments - licenses 2

​

 

724

​

 

—

​

 

724

​

 

696

​

 

—

​

 

696

Anti-itch product installment payments

​

 

57

​

​

—

​

 

57

​

 

2

​

 

—

​

 

2

LOC fees

​

​

16

​

​

​

​

​

16

​

​

—

​

​

—

​

​

—

Total Interest Expense and Financing Fee

​

$

4,462

​

$

2,572

​

$

7,034

​

$

698

​

$

—

​

$

698

Note 1:Amortization of fees in connection with debt raises.

Note 2: Imputed interest expense related to Ximino, Accutane and anti-itch cream acquisitions.